Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Dermatology"
DOI: 10.1111/bjd.19750
Abstract: Checkpoint inhibitor (CPI) therapy has vastly improved long‐term outcomes in metastatic malignant melanoma (MMM). Therapy takes the form of monoclonal antibody infusions that target immune cell checkpoint proteins, such as cytotoxic T‐lymphocyte‐associated protein 4 (CTLA4)… read more here.
Keywords: immune related; cutaneous iraes; cutaneous immune; checkpoint ... See more keywords